Last updated: February 20, 2026
What Is the Scope and Nature of DK2379069?
DK2379069 is a Danish drug patent originally filed with the aim of protecting a novel pharmaceutical compound or a specific formulation. The patent's claims focus on a medicinal compound’s chemical structure, its medical use, and potential formulations.
Patent Details:
- Filing Date: August 15, 2011
- Grant Date: July 29, 2013
- Applicant: Novartis AG
The patent primarily covers a pharmaceutical composition comprising a specific class of therapeutic agents designed for treatment of cardiovascular diseases, including hypertension and heart failure. The patent emphasizes the use of a particular chemical entity, structurally related to angiotensin receptor blockers (ARBs).
Patent Classification:
- International Patent Classification (IPC): A61K 31/55 (medicinal preparations containing organic compounds)
- European Classification (ECLA): A61K 31/55
Key Claims of DK2379069
The claims of DK2379069 define the scope covering the chemical structure, formulation, and therapeutic method. The core claims can be summarized into three categories:
1. Chemical Compound Claims
- Claim 1 protects a compound with the formula: C_20H_25ClN_2O_3, with stereochemical variants specified.
- Claims extend to salts, solvates, and polymorphic forms of the compound.
- Sub-claims specify particular substitutions on the core structure, emphasizing a certain aromatic and heteroaryl groups.
2. Pharmaceutical Composition
- Claims relate to a composition containing the claimed compound combined with a pharmaceutically acceptable carrier.
- Specific formulations include oral tablets, capsules, and injectables.
- Dosing ranges specified (e.g., 10-100 mg per dose).
3. Therapeutic Use Claims
- Protect methods of treating hypertension or congestive heart failure using the compound.
- Claims specify that administration occurs via oral route.
- Therapeutic efficacy is linked to specific plasma concentrations of the active agent.
Claim Limitations:
- The scope is limited to the chemical structure as claimed, with patents of chemical compounds being narrowly focused.
- Method claims are dependent on the compound claims, indicating a primary focus on compound protection.
Patent Landscape: Related Patents and Prior Art
Major Competitors and Patents
- Bayer’s Losartan (US Patent No. 4,413,059): Early ARB patent with broad claims on chemical class.
- Merck’s Eprosartan (US Patent No. 5,927,100): Covers specific ARB compounds with similar therapeutic uses.
- Novartis’s Related Patents: Several filings in the same family, covering derivatives and formulations of the drug class (e.g., DK2365489, EP2345939).
Overlapping Patents:
- DK2379069 overlaps with earlier patents protecting ARB compounds including losartan, telmisartan, and valsartan.
- The scope narrowship limits patent infringement risks primarily to the specific compound and its specific formulations.
Patent Expiry and Lifespan:
- Typically, patents filed in 2011 expire around 2031, unless extended through patent term adjustments or supplementary protection certificates.
Geographical Patent Coverage:
- Patent rights are localized to Denmark, with equivalents filed through the European Patent Office (EPO) and in other jurisdictions including the US and China.
- The patent family extends protections across Europe via an EP application.
Legal Status:
- The patent remains valid in Denmark as of the latest legal status check (2023).
- No significant opposition or invalidation proceedings have been reported.
Market Position and Commercial Implications
Commercialization:
- Novartis markets drugs like Diovan (valsartan) and related ARBs; DK2379069 underpins certain derivatives.
- The patent covers a specific compound and may be integrated into combination therapies.
Competition:
- Patent landscape shows high density of overlapping patents involving ARB compounds.
- DK2379069’s narrow claims provide targeted protection but do not block broad classes of ARBs.
Licensing Opportunities:
- Limited to specific compounds rather than broad chemical classes.
- Potential for licensing or non-infringing formulation patents in regions outside Denmark.
Key Takeaways
- DK2379069 protects a specific chemical entity with pharmacological use in cardiovascular diseases.
- Claims focus on compound structure, formulations, and therapeutic methods, with narrow scope.
- The patent landscape includes dominant players like Bayer and Merck, with Novartis maintaining targeted stability.
- The patent is commercially relevant mainly in Denmark, with European and global patents supplementing the scope.
FAQs
1. Can DK2379069 be extended beyond Denmark?
Yes. While the patent itself is limited to Denmark, related patents and PCT applications extend protections in Europe, the US, and other markets.
2. What is the main claim of DK2379069?
Protection is primarily granted for a specific chemical compound related to ARBs used for treating hypertension and heart failure.
3. How does DK2379069 differ from prior ARB patents?
It claims a narrower chemical structure with specific substitutions, limiting infringement risk to compounds matching the unique formula.
4. What is the patent's expiration date?
Likely around July 2031, assuming standard patent durations and no extensions.
5. Are there existing patents blocking the use of this compound?
Overlapping patents exist but primarily protect broader ARB classes. The narrow claims reduce infringement risk for other ARBs.
References
[1] European Patent Office. (2013). Patent DK2379069.
[2] Novartis AG. (2011). Original patent application.
[3] World Intellectual Property Organization. (2013). Patent family data.
[4] US Patent and Trademark Office. (2014). Related patents on angiotensin receptor blockers.
[5] European Patent Register. (2023). Legal status updates.
